191 related articles for article (PubMed ID: 19160072)
1. Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.
Wootla B; Rao DN; Friboulet A; Uda T; Lacroix-Desmazes S; Kaveri SV
Clin Rev Allergy Immunol; 2009 Oct; 37(2):97-104. PubMed ID: 19160072
[TBL] [Abstract][Full Text] [Related]
2. Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.
Wootla B; Dasgupta S; Mallet V; Kazatchkine MD; Nagaraja V; Friboulet A; Kaveri SV; Lacroix-Desmazes S
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):229-34. PubMed ID: 16651863
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to factor VIII with catalytic activity.
Bayry J; Lacroix-Desmazes S; Pashov A; Stahl D; Hoebeke J; Kazatchkine MD; Kaveri SV
Autoimmun Rev; 2003 Jan; 2(1):30-5. PubMed ID: 12848973
[TBL] [Abstract][Full Text] [Related]
5. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.
Lacroix-Desmazes S; Wootla B; Dasgupta S; Delignat S; Bayry J; Reinbolt J; Hoebeke J; Saenko E; Kazatchkine MD; Friboulet A; Christophe O; Nagaraja V; Kaveri SV
J Immunol; 2006 Jul; 177(2):1355-63. PubMed ID: 16818797
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies with enzymatic properties in human autoimmune diseases.
Wootla B; Lacroix-Desmazes S; Warrington AE; Bieber AJ; Kaveri SV; Rodriguez M
J Autoimmun; 2011 Sep; 37(2):144-50. PubMed ID: 21624820
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of proteolytic antibodies against factor VIII in hemophilia A.
Lacroix-Desmazes S; Bayry J; Misra N; Horn MP; Villard S; Pashov A; Stieltjes N; d'Oiron R; Saint-Remy JM; Hoebeke J; Kazatchkine MD; Reinbolt J; Mohanty D; Kaveri SV
N Engl J Med; 2002 Feb; 346(9):662-7. PubMed ID: 11870243
[TBL] [Abstract][Full Text] [Related]
9. Catalytic antibodies to factor VIII in haemophilia A.
Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S31-4. PubMed ID: 14567533
[TBL] [Abstract][Full Text] [Related]
10. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y
Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758
[TBL] [Abstract][Full Text] [Related]
11. Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
Lacroix-Desmazes S; Moreau A; Sooryanarayana ; Bonnemain C; Stieltjes N; Pashov A; Sultan Y; Hoebeke J; Kazatchkine MD; Kaveri SV
Nat Med; 1999 Sep; 5(9):1044-7. PubMed ID: 10470082
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII inhibitor with catalytic activity towards factor VIII.
Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Kazatchkine MD; Kaveri SV
Haematologica; 2000 Oct; 85(10 Suppl):89-92. PubMed ID: 11187883
[TBL] [Abstract][Full Text] [Related]
13. Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A.
Lacroix-Desmazes S; Misra N; Bayry J; Villard S; Kazatchkine MD; Kaveri SV
J Immunol Methods; 2002 Nov; 269(1-2):251-6. PubMed ID: 12379365
[TBL] [Abstract][Full Text] [Related]
14. Acquired inhibitors.
Cohen AJ; Kessler CM
Baillieres Clin Haematol; 1996 Jun; 9(2):331-54. PubMed ID: 8800509
[TBL] [Abstract][Full Text] [Related]
15. High levels of catalytic antibodies correlate with favorable outcome in sepsis.
Lacroix-Desmazes S; Bayry J; Kaveri SV; Hayon-Sonsino D; Thorenoor N; Charpentier J; Luyt CE; Mira JP; Nagaraja V; Kazatchkine MD; Dhainaut JF; Mallet VO
Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4109-13. PubMed ID: 15743915
[TBL] [Abstract][Full Text] [Related]
16. Circulating FVIII-specific IgG, IgA and IgM memory B cells from haemophilia A patients.
Diaz I; Bolloré K; Tuaillon E; Lapalud P; Giansily-Blaizot M; Vendrell JP; Schved JF; Lavigne-Lissalde G
Haemophilia; 2016 Sep; 22(5):799-805. PubMed ID: 27439547
[TBL] [Abstract][Full Text] [Related]
17. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates.
Di Giambattista M; Branckaert T; Hougardy V; Kemball-Cook G; Laub R
Mol Immunol; 2007 Mar; 44(8):1903-13. PubMed ID: 17113150
[TBL] [Abstract][Full Text] [Related]
18. Nature and nurture of catalytic antibodies.
Paul S; Planque SA; Nishiyama Y; Hanson CV; Massey RJ
Adv Exp Med Biol; 2012; 750():56-75. PubMed ID: 22903666
[TBL] [Abstract][Full Text] [Related]
19. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
Algiman M; Dietrich G; Nydegger UE; Boieldieu D; Sultan Y; Kazatchkine MD
Proc Natl Acad Sci U S A; 1992 May; 89(9):3795-9. PubMed ID: 1570298
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG.
Moreau A; Lacroix-Desmazes S; Stieltjes N; Saenko E; Kaveri SV; D'Oiron R; Sultan Y; Scandella D; Kazatchkine MD
Blood; 2000 Jun; 95(11):3435-41. PubMed ID: 10828026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
